We hypothesized that coupling the high-affinity anti-B7-H3 affibody with the membrane-disruptive peptide MAG2 would synergistically enhance the antileukemic effect by selectively targeting AML cells. The gene discussed is RETREG2; the disease is acute myeloid leukemia.